The Treg Cell-Based Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Treg Cell-Based Therapies Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Treg Cell-Based Therapies Market.
Some of the key takeaways from the Treg Cell-Based Therapies Pipeline Report:
Companies across the globe are diligently working toward developing novel Treg Cell-Based Therapies treatment therapies with a considerable amount of success over the years.
Treg Cell-Based Therapies companies working in the treatment market are HCW Biologics, Sangamo Therapeutics, Gentibio, Abata Therapeutics, NightHawk Biosciences, Sangamo Therapeutics, Quell Therapeutics Limited, Coya Therapeutics, Orca Bio, and others, are developing therapies for the Treg Cell-Based Therapies treatment
Emerging Treg Cell-Based Therapies therapies such as – HCW9302, KITE-037, GNTI-122, ABA-101, PTX-35, TX200, QEL-001, Coya 101, Orca-T, and others are expected to have a significant impact on the Treg Cell-Based Therapies market in the coming years.
In August 2022, In order to extend its activities in Seattle and supplement its current R&D enterprise in South San Francisco, Sonoma Biotherapeutics, Inc. announced that it has entered into a leasing agreement to create an approximately 83,000 square foot Research and Development (R&D) and Manufacturing Centre.The cutting-edge Centre assisted Sonoma Bio’s pipeline of gene-modified Treg treatments for autoimmune and inflammatory illnesses with R&D and mass production
In August 2022, In order to re-establish immunological tolerance and repair tissue in patients with inflammatory bowel disorders (IBD), GentiBio, Inc. revealed that it had partnered with Bristol Myers Squibb. The partnership combines Bristol Myers Squibb’s expertise in cell treatments and immunology with GentiBio’s unique designed Treg platform for producing scalable, stable, highly-selective, and durable Tregs
In June 2022, Coya Therapeutics, Inc. disclosed that it has received about $10.3 million from accredited and institutional investors. With the fundraising, the amount of money raised so far exceeds $20 million. The money is utilised to push several Treg programmes through Phase I and Phase IIb clinical trials aimed at autoimmune and neurological illnesses
Treg Cell-Based Therapies Overview
Clinical trials of cellular therapies for the treatment of autoimmune illnesses, transplant rejection, and graft-versus-host disease are now taking place. These therapies use regulatory T (Treg) cells. Treg cell therapy has demonstrated early promise in the treatment of graft-versus-host disease, type 1 diabetes, and organ transplant recipients. It has also demonstrated promise as a potential treatment for other conditions.
Get a Free Sample PDF Report to know more about Treg Cell-Based Therapies Pipeline Therapeutic Assessment-
Emerging Treg Cell-Based Therapies Drugs Under Different Phases of Clinical Development Include:
HCW9302: HCW Biologics
KITE-037: Sangamo Therapeutics
ABA-101: Abata Therapeutics
PTX-35: NightHawk Biosciences
TX200: Sangamo Therapeutics QEL-001: Quell Therapeutics Limited
Coya 101: Coya Therapeutics
Orca-T: Orca Bio
Treg Cell-Based Therapies Pipeline Therapeutics Assessment
Treg Cell-Based Therapies Assessment by Product Type
Treg Cell-Based Therapies By Stage and Product Type
Treg Cell-Based Therapies Assessment by Route of Administration
Treg Cell-Based Therapies By Stage and Route of Administration
Treg Cell-Based Therapies Assessment by Molecule Type
Treg Cell-Based Therapies by Stage and Molecule Type
DelveInsight’s Treg Cell-Based Therapies Report covers around products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Treg Cell-Based Therapies product details are provided in the report. Download the Treg Cell-Based Therapies pipeline report to learn more about the emerging Treg Cell-Based Therapies therapies
Some of the key companies in the Treg Cell-Based Therapies Therapeutics Market include:
Key companies developing therapies for Treg Cell-Based Therapies are – Orca Bio, Caladrius Biosciences, Sangamo Therapeutics, Cellenkos, VT BIO, Rapa Therapeutics, Quell Therapeutics, Coya Therapeutics, Sonoma Biotherapeutics, GentiBio, AstraZeneca, TCR² Therapeutics, KSQ Therapeutics, Kyverna Therapeutics, Astellas, Abata Therapeutics, TRACT Therapeutics, Adaptive Biotechnologies, PolTREG, TeraImmune, and others.
Treg Cell-Based Therapies Pipeline Analysis:
The Treg Cell-Based Therapies pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Treg Cell-Based Therapies with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Treg Cell-Based Therapies Treatment.
Treg Cell-Based Therapies key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Treg Cell-Based Therapies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Treg Cell-Based Therapies market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Treg Cell-Based Therapies drugs and therapies
Treg Cell-Based Therapies Pipeline Market Drivers
High prevalence of autoimmune and inflammatory diseases, the emergence of new techniques such as next-generation T-cells immunotherapy are some of the important factors that are fueling the Treg Cell-Based Therapies Market.
Treg Cell-Based Therapies Pipeline Market Barriers
However, high cost associated with the Treg Cell-Based Therapies, the complex manufacturing of regulatory T-cell immunotherapies and other factors are creating obstacles in the Treg Cell-Based Therapies Market growth.
Scope of Treg Cell-Based Therapies Pipeline Drug Insight
Key Treg Cell-Based Therapies Companies: HCW Biologics, Sangamo Therapeutics, Gentibio, Abata Therapeutics, NightHawk Biosciences, Sangamo Therapeutics, Quell Therapeutics Limited, Coya Therapeutics, Orca Bio, and others
Key Treg Cell-Based Therapies Therapies: HCW9302, KITE-037, GNTI-122, ABA-101, PTX-35, TX200, QEL-001, Coya 101, Orca-T, and others
Treg Cell-Based Therapies Therapeutic Assessment: Treg Cell-Based Therapies current marketed and Treg Cell-Based Therapies emerging therapies
Treg Cell-Based Therapies Market Dynamics: Treg Cell-Based Therapies market drivers and Treg Cell-Based Therapies market barriers
Request for Sample PDF Report for Treg Cell-Based Therapies Pipeline Assessment and clinical trials
Table of Contents
Treg Cell-Based Therapies Report Introduction
Treg Cell-Based Therapies Executive Summary
Treg Cell-Based Therapies Overview
Treg Cell-Based Therapies- Analytical Perspective In-depth Commercial Assessment
Treg Cell-Based Therapies Pipeline Therapeutics
Treg Cell-Based Therapies Late Stage Products (Phase II/III)
Treg Cell-Based Therapies Mid Stage Products (Phase II)
Treg Cell-Based Therapies Early Stage Products (Phase I)
Treg Cell-Based Therapies Preclinical Stage Products
Treg Cell-Based Therapies Therapeutics Assessment
Treg Cell-Based Therapies Inactive Products
Company-University Collaborations (Licensing/Partnering) Analysis
Treg Cell-Based Therapies Key Companies
Treg Cell-Based Therapies Key Products
Treg Cell-Based Therapies Unmet Needs
Treg Cell-Based Therapies Market Drivers and Barriers
Treg Cell-Based Therapies Future Perspectives and Conclusion
Treg Cell-Based Therapies Analyst Views
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:27 Drydock Ave S. Jones Blvd #2432
Country: United States